Cargando…
Discussing Cervical Cancer Screening Options: Outcomes to Guide Conversations Between Patients and Providers
Purpose. In 2018, the US Preventive Services Task Force (USPSTF) endorsed three strategies for cervical cancer screening in women ages 30 to 65: cytology every 3 years, testing for high-risk types of human papillomavirus (hrHPV) every 5 years, and cytology plus hrHPV testing (co-testing) every 5 yea...
Autores principales: | Holt, Hunter K., Kulasingam, Shalini, Sanstead, Erinn C., Alarid-Escudero, Fernando, Smith-McCune, Karen, Gregorich, Steven E., Silverberg, Michael J., Huchko, Megan J., Kuppermann, Miriam, Sawaya, George F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440733/ https://www.ncbi.nlm.nih.gov/pubmed/32885045 http://dx.doi.org/10.1177/2381468320952409 |
Ejemplares similares
-
Changing Preferences for a Cervical Cancer Screening Strategy: Moving Away from Annual Testing
por: Schrier, Elizabeth, et al.
Publicado: (2022) -
Prioritizing cervical cancer screening services during the COVID-19 pandemic: Response of an academic medical center and a public safety net hospital in California
por: Sawaya, George F., et al.
Publicado: (2021) -
A Randomized Trial Comparing the Diagnostic Accuracy of Visual Inspection with Acetic Acid to Visual Inspection with Lugol’s Iodine for Cervical Cancer Screening in HIV-Infected Women
por: Huchko, Megan J., et al.
Publicado: (2015) -
Performance of p16(INK4a) ELISA as a primary cervical cancer screening test among a large cohort of HIV-infected women in western Kenya: a 2-year cross-sectional study
por: Wu, Tara J, et al.
Publicado: (2016) -
Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome
por: Vreede, Andrew P., et al.
Publicado: (2019)